Oxaliplatin
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by infusion into a vein. Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts.
Other serious side effects include allergic reactions. Use in pregnancy is known to harm the baby. Oxaliplatin is in the platinum-based antineoplastic family of medications.
It is believed to work by blocking the duplication of DNA. Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe. It is on the 2023 World Health Organization's List of Essential Medicines.
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by infusion into a vein. Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts.
Other serious side effects include allergic reactions. Use in pregnancy is known to harm the baby. Oxaliplatin is in the platinum-based antineoplastic family of medications.
It is believed to work by blocking the duplication of DNA. Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe. It is on the 2023 World Health Organization's List of Essential Medicines.
History
Oxaliplatin was first synthesized in 1978 at Nagoya City University by Yoshinori Kidani. It was later developed in Europe as a less toxic and more effective alternative to cisplatin. It gained European approval in 1996, and approval by the U.S. Food and Drug Administration in 2002.
Generic oxaliplatin was first approved in the United States in August 2009. Patent disputes caused generic production to stop in 2010, but it restarted in 2012.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1306024807 under CC BY-SA 4.0; modifications have been made.